HemaCare is committed to supporting the next generation of science and technology professionals through community outreach and educational programs. In a world that is increasingly reliant on science and technology, STEM education provides students with the necessary skill sets to enter the modern workforce. The STEM (Science, Technology, Engineering, and Math) initiative is based on the premise that these fields should be taught using an integrative approach that focuses on real-world applications, rather than teaching each field in isolation. The hope is to instill in our young people not just the skills of their chosen field, but a more critical way of thinking, understanding, and exploring the world.
The U.S. Food and Drug Administration (FDA) has announced that they are adding staff and rolling out policy changes aimed at advancing the development of safe and effective cell and gene therapies.  The announcement came in the form of a press release on January 15th, citing that the new policies are a response to the current surge in cell and gene therapy products that the agency is handling. Based on the number of investigational new drug (IND) applications being submitted, the FDA projects a significant rise in the number of therapies that will be approved over the next few years:
An independent publication cites using HemaCare primary T-cells to investigate a novel cancer therapy based on blocking immune suppression while simultaneously promoting T-cell activity. 
Newly approved T-cell therapies have been eliciting enthusiastic discussion across the medical field for their unparalleled success rate in treating aggressive blood cancers. This success has unfortunately not extended to the treatment of brain tumors, where upregulation of the “immune checkpoint” molecule PDL-1 interferes with normal immune response. Now a research group based at the University of Alabama’s Medical School may have found a way to outsmart brain cancer cells that evade the body’s immune system.
HemaCare Corporation’s new global headquarters is officially open for business! The company started 2019 in a brand new 40,000 square foot space in a newly modernized 44-acre corporate campus located in the heart of the San Fernando Valley at Northridge. The design and construction of the cutting-edge facility provide a spacious workspace that promotes the well-being of its occupants, while significantly expanding the company’s on-site capabilities.
In an independent study recently published by Pfizer,  natural killer (NK) immune cells sourced from HemaCare were evaluated to test how well suited they are for use in cytotoxic activity assays.
These last few years have seen the successful clinical development of several monoclonal antibody-based treatments for cancer and inflammatory disease. These antibodies are designed to act in a number of different ways, from tagging target cells so they can be recognized by the immune system, to blocking growth or metastasis, to attacking problematic cells themselves. Monoclonal antibodies (m’Abs) are seen as particularly beneficial because they can be used to complement more traditional therapies and because their use generally results in fewer side effects.